10 results about "Immunodominant Epitopes" patented technology

This invention discloses a recombinant adenovirus vaccine targeting the Tp0326 antigen and its preparation method, comprising a recombinant adenovirus vector and the Tp0326 antigen expressed therein. The recombinant adenovirus vector uses a replication-defective human adenovirus type 5 (Ad5) as a backbone, inserting the full-length Tp0326 antigen gene of *Treponema pallidum* into the adenovirus shuttle vector pshuttle-IRES-rGFP-1, and obtaining it through homologous recombination with the adenovirus backbone plasmid pAdEasy-1. This invention, using a replication-defective Ad5 as a vector, provides a recombinant adenovirus vaccine with high safety and efficient expression of the full-length Tp0326 antigen. The expressed antigen has a natural conformation, retains the ECL4 immunodominant epitope, and is more likely to induce a specific immune response, resulting in stronger immunogenicity. The preparation method involves constructing a recombinant adenovirus vector through homologous recombination, packaging it in HEK293T cells, and purifying it by CsCl density gradient centrifugation to obtain a high-purity, high-titer recombinant adenovirus vaccine suitable for large-scale production. The recombinant adenovirus vaccine can be administered via intramuscular or intranasal injection.

The invention provides recombinant II-type collagen as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The recombinant II-type collagen monomer is obtained by splicing Gly-X-Y repetitive gene sequences of multiple sections of triple helix regions in human II-type collagen, immunodominant epitopes, unstable amino acid sequence 3 conjunctions and glycosylation sites are avoided during selection, then the recombinant II-type collagen monomer is repeated for multiple times, and the recombinant II-type collagen monomer is obtained. The recombinant II type collagen with the molecular weight of 40-50 kDa is obtained; the recombinant II-type collagen is beneficial to expression of pichia pastoris, has the effects of promoting adhesion and migration of cartilage cells, can also promote differentiation into cartilage cells, and has good practicability.

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

The invention relates to the field of molecular vaccinology, in particular to a vaccine aiming at severe malaria, and further relates to a multi-epitope fusion antigen vaccine derived from plasmodium falciparum STEVOR protein as well as preparation and application of the multi-epitope fusion antigen vaccine. The multi-epitope fusion antigen vaccine contains at least two amino acid fragments in a B cell epitope, a CD4 and T cell epitope and a CD8 and T cell epitope. The MEFA vaccine targeting STEVOR protein SC structural domain conservative immunodominant epitopes has broad spectrum, can realize 97.15% global HLA coverage rate through the conservative epitopes, can synchronously induce IgG antibody and CD4 + / CD8 + T cell response, is safe, has no toxicity / sensitization, and has good in-vivo and in-vitro stability (the mammalian half-life period gt; further, the strain is used for inducing wide immune response for resisting severe malaria, and is suitable for large-scale production of an escherichia coli or yeast expression system.

The invention provides a T cell immunodominance epitope peptide of an SARS-CoV-2 nucleocapsid protein mutation site and application of the T cell immunodominance epitope peptide, and belongs to the technical field of biological medicine. According to the invention, a group of dominant epitope peptide compounds capable of specifically targeting mutation sites and activating T cell response are developed by screening and identifying dominant epitopes aiming at N protein of an Omicron mutant strain JN.1 substrain. The epitope peptide can induce an organism to generate an effective specific T cell immune response aiming at a current main epidemic Omicron pedigree JN.1 substrain mutation site, so that the cellular immunocompetence of the organism is enhanced. A novel coronavirus vaccine, a medicine or an antigen detection kit developed based on the epitope peptide compound can provide possibility for effectively removing virus infected cells, reducing continuous existence of viruses in vivo and identifying new coronavirus infection, so that SARS-CoV-2 breakthrough infection is diagnosed and prevented in an early stage, and the long-term health burden of a patient is relieved.

The invention relates to a human parainfluenza virus recombinant multi-genotype chimeric antigen with large expression quantity, good solubility and natural conformation, which is characterized in that a plurality of immunodominant epitope regions which are not in cross reaction with other pathogens are subjected to chimeric expression with fusion protein and are mutually spaced through connecting peptides, and when the human parainfluenza virus recombinant multi-genotype chimeric antigen is used for immunodetection of a parainfluenza virus antibody by ELISA (enzyme-linked immuno sorbent assay) or chromatography, the human parainfluenza virus recombinant multi-genotype chimeric antigen can be used for immunodetection of a parainfluenza virus antibody. The sensitivity and the specificity of the existing kit can be improved.

The application provides a T cell immune dominant epitope peptide of a SARS-CoV-2 nucleocapsid protein mutation site and an application thereof, and belongs to the technical field of biological medicines. The application develops a dominant epitope peptide as shown in SEQ ID NO. 12 which can specifically target a mutation site and activate a T cell response by screening and identifying a dominant epitope for the N protein of the Omicron mutant strain JN.1 subline. The epitope peptide can induce the body to produce an effective specific T cell immune response against the currently prevailing Omicron subline JN.1 subline mutation site, and enhance the cellular immune capacity of the body. A novel coronavirus vaccine, a drug or an antigen detection kit developed based on the epitope peptide complex can provide a possibility for effectively eliminating virus-infected cells, reducing the persistence of viruses in the body and identifying coronavirus infection, thereby early diagnosing, preventing and treating SARS-CoV-2 breakthrough infection and reducing the long-term health burden of patients.

The present invention discloses a Klebsiella pneumoniae vaccine fusion antigen mHla-EpiVac, the amino acid sequence of the antigen protein is shown in SEQ ID NO: 1. Wherein mHla is a non-toxic mutant of Staphylococcus aureus α-hemolysin, which can form a heptamer as a carrier protein of the epitope; EpiVac contains three immunodominant epitopes of Klebsiella pneumoniae, which are connected by a linker. The present invention also discloses a preparation method and application of the antigen protein. The antigen protein prepared by the method of the present invention can effectively stimulate the body to produce an efficient humoral response and a cellular immune response, and can provide a significant protective effect against a lethal dose of Klebsiella pneumoniae infection, and can be used as a candidate antigen for the Klebsiella pneumoniae vaccine.

A system and method for prediction of immunodominant epitopes is provided herein. MHCII peptidomics was used to discover complex bacterial epitopes and host antigen processing pathways. Novel insights into the features of antigenicity are leveraged to build an algorithm for prediction of immunodominant epitopes. Use of immunodominant epitopes is described.

The present application relates to the field of biotechnology, and particularly relates to a porcine transmissible gastroenteritis virus epitope vaccine, a preparation method and application thereof, and FliC S.T The amino acid sequence of the TGEV-S fusion protein is shown as SEQ ID NO. 3, and the nucleotide sequence is shown as SEQ ID NO. 4. The fusion protein FliCS.T-TGEV-S prepared in the present application is an epitope vaccine based on the dominant antigen epitope of TGEV, which combines the immunodominant epitope, fusion protein technology and advanced genetic engineering methods to enhance the specificity and protection effect of the vaccine. The vaccine can not only induce high-level antibody response and effectively inhibit TGEV infection, but also has high safety and stability. Compared with the traditional vaccine, the vaccine of the present application has significant advantages in production cost, immunization efficacy, protection durability and the like, and provides a feasible TGE prevention and control scheme for the pig industry.